申请人:Incyte Corporation
公开号:US10738052B2
公开(公告)日:2020-08-11
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物,它们是激酶(如 c-Met)的抑制剂,可用于治疗癌症和其他与激酶通路失调有关的疾病。